

## Investigation into Mixture found in FTA Evidence Sample (barcode [REDACTED])

Maria Aquilera, Scientist, Allan McNevin, Senior Scientist,  
DNA Analysis, Forensic and Scientific Services, Queensland Health.

### Abstract

On the 24<sup>th</sup> of May 2008, during the Genescan analysis of capillary electrophoresis batch CEPRF20080521\_01 (to become batch GEN9REF20080526\_01), a mixture was noted in FTA sample barcode [REDACTED]. Initially FTA sample [REDACTED] was processed through routine FTA processing procedures (as outlined above) on batch FTA20080207\_01 (to become GEN9REF20080225\_03), and yielded no DNA profile. An investigation under OQI # 19767 commenced to determine the cause for this mixture. [REDACTED]

### Background

Within DNA Analysis processing of person (Reference) samples is performed using FTA [REDACTED] are transferred onto FTA<sup>TM</sup> paper and provided to the laboratory, or whole blood is provided and this transferred to the FTA<sup>TM</sup> paper within the laboratory.

These samples are processed through standard laboratory procedures. Briefly, punches of FTA paper were transferred to a 96-well half-skirt PCR plates using the BSD Duet 600 (BSD Robotics, Australia) semi automated dried sample punch instrument. The dried punches were washed with TE buffer (blood punches were washed in weak NaOH solution followed by TE buffer), and dried on a hot block. The samples are then processed through to STR PCR amplification. This was performed by the addition of TE and PCR mastermix (Applied Biosystems AMPF $\phi$ STR<sup>®</sup> Profiler Plus<sup>®</sup> PCR Amplification kit), the plate was sealed and amplified on a GeneAmp<sup>®</sup> PCR System 9700 thermocycler. After amplification stage, fragment analysis was performed on a portion of the PCR product by capillary electrophoresis on the Applied Biosystems Prism<sup>®</sup> 3130xl Genetic Analyser, and the data analysed using a combination of Genescan (version 3.7.2) with Genotyper (version 3.7.1) software.

If an unacceptable profile was obtained further processing would be required, depending on the sample and result, the sample may have been re-processed through the procedure outlined above with the same, more or less punches of the FTA paper. If these results were still unacceptable further processing was performed. This involved further punches (with a larger manual hole punch) being placed into individually labelled DNA free 1.5mL tubes. The punches were then transferred to a Slicprep<sup>TM</sup> 96 device (Promega) via the use of the *Automate.it* STORstar system (Process Analysis & Automation Ltd. Hampshire. UK). There were then processed through automated DNA extraction on a PerkinElmer MultiPROBE<sup>®</sup> II PLUS HT EX with Gripper<sup>TM</sup> Integration platform with Promega DNA IQ<sup>TM</sup> DNA extraction kit. Each extraction batch includes a positive and negative extraction control and a negative punching control for quality purposes. All samples on the one batch are processed under the same conditions as each other according standard laboratory procedures (QIS document 1897).

After extraction, between and after the following processes, the DNA extracts were stored frozen at -20°C. Following extraction, the DNA extracts were then quantified using Applied Biosystems Quantifiler<sup>®</sup> Human DNA Quantification Kit on an Applied Biosystems Prism 7000 Sequence Detection System real-time PCR instrument. The DNA extract was then amplified using Applied Biosystems AMPF $\phi$ STR<sup>®</sup> Profiler Plus<sup>®</sup> amplification kit on a Perkin Elmer GeneAmp 9700. The PCR product was then prepared for capillary electrophoresis and run through an Applied Biosystems Prism 3130xl Genetic Analyser and analysed using Genescan (version 3.7.2) and Genotyper (version 3.7.1) software.

# CaSS | Forensic and Scientific Services

A CLINICAL AND STATEWIDE SERVICE

## Investigation

On the 24<sup>th</sup> of May 2008, during the Genescan analysis of capillary electrophoresis batch CEPRF20080521\_01 (to become batch GEN9REF20080526\_01), a mixture was noted in FTA sample barcode [REDACTED]. Initially FTA sample [REDACTED] processed through routine FTA processing procedures (as outlined above) on batch FTA20080207\_01 (to become GEN9REF20080225\_03), and yielded no DNA profile. The sample was reprocessed with extra punches on batch FTARUN20080318\_02 (to become batch GEN9REF20080423\_04). This resulted in a partial DNA profile shown in Figure 1 below.





Figure 1. FTA Sample [REDACTED] from batch GEN9REF20080423\_04.

The FTA sample was further processed through automated extraction procedures outlined above on batch FTAEXT20080515\_01 (to become batch RFIQEXT20080515\_01). After extraction, the sample was processed through routine quantification and amplification procedures as outlined above. The DNA extract yielded a quantification value of 0.0558ng/ $\mu$ L, resulting in 20 $\mu$ L of the DNA extract being added to the amplification reaction. This amplified product was analysed on capillary electrophoresis batch CEPRF20080521\_01 (to become batch GEN9REF20080526\_01). This yielded a mixed DNA profile shown in Figure 2 below.

# CaSS | Forensic and Scientific Services

A CLINICAL AND STATEWIDE SERVICE



**Figure 2.** Profile obtained for sample [REDACTED] after extraction on MPII.

The sample [REDACTED] was reprepared and re-run on the [REDACTED] Genetic Analyser and re-analysed [REDACTED] Genescan software. The mixed DNA profile was shown to be reproducible.

The DNA extract was re-amplified on amplification batch 9AMPR200820080527\_01 (to become batch GEN9REF20080602\_02). The mixed DNA profile was shown to be reproducible as shown in Figure 3 below.

# CaSS | Forensic and Scientific Services

A CLINICAL AND STATEWIDE SERVICE




Figure 3. Profile obtained for sample [redacted] after re-amplification.

This demonstrates that the DNA extract of sample [redacted] was contaminated with a second DNA [redacted] re-extraction for the FTA sample [redacted] performed under barcode [redacted] and this yielded a full 9-loci single source DNA profile shown in Figure 4 below.



# CaSS | Forensic and Scientific Services

A CLINICAL AND STATEWIDE SERVICE




Figure 4. Profile obtained for sample [redacted] after re-extraction as barcode [redacted]

This profile was consistent with [redacted] original partial profile shown in Figure 1 above.

The mixed DNA profile from barcode [redacted] was separated into the known DNA profile and the [redacted] profile contributing to the [redacted] then searched against a [redacted] obtained from samples on extraction batch RFIQEXT20080515\_01. A match was found with sample [redacted]. This is shown in Table 1 below.

Table 1. Summary of results for FTA sample 184858899.

Sample	Processing	Amel	D3	D8	D5	vWA	D21	D13	FGA	D7	D18
[redacted]	FTA	X, Y	15, 18	12, 14	11, NR	15, 18	28, 29	9, NR	17, 22	NSD	NSD
[redacted]	DNA IQ extraction	X, Y	15, 18, 19	12, 13, 14, 15	9, 11, 12	14, 15, 17, 18	28, 29, 30, 31.2	9, 12, 14	17, 21, 22, 25	10, 11	12, 17, 20
[redacted]	DNA IQ extraction	X, Y	15, 18	12, 14	11, 12	15, 18	28, 29	9, 12	17, 22	10, 11	12, 17
[redacted]	[redacted]	X, Y	15, 19	13, 15	9, 12	14, 17	30, 31.2	12, 14	21, 25	10, 11	12, 17, 20
[redacted]	DNA IQ extraction	X, Y	15, 19	13, 15	9, 12	14, 17	30, 31.2	12, 14	21, 25	10, 11	12, 20

NR = no reportable allele, NSD = No Sizing Data (no alleles detected), \*333806165 was a re-extraction of 184858899

A representation of the plate layout for extraction batch RFIQEXT20080515\_01 is shown in Figure 5 below, with the relative positions of samples [redacted] indicated in yellow and green respectively.

# CaSS | Forensic and Scientific Services

A CLINICAL AND STATEWIDE SERVICE

	1	2	3	4	5	6	7	8	9	10	11	12
A	POS	sample	sample	sample	sample	sample	sample	sample	sample	sample	sample	sample
B	NEG	sample	sample	sample	sample	sample	sample	sample	sample	sample	sample	sample
C	NEG	sample	sample	sample	sample	sample	sample	sample	sample	sample	sample	empty
D	sample	sample	sample	sample	sample	sample	sample	sample	sample	sample	sample	empty
E	sample	sample	sample	sample	sample	sample	sample	sample	sample	sample	sample	empty
F	sample	sample	sample	sample	sample	sample	sample	sample	sample	sample	sample	empty
G	sample	sample	sample	sample	sample	sample	sample	sample	sample	sample	sample	empty
H	sample	sample	sample	sample	sample	sample	sample	sample	sample	sample	sample	empty

Figure 5. Plate layout for extraction batch RFIQEXT20080515\_01

The profile obtained from extraction batch RFIQEXT20080515\_01 for sample [redacted] was consistent with all 16 alleles obtained from previous FTA processing of the same sample. Therefore the profile that was obtained from this sample was not from an exogenous source. The presence of a reproducible DNA profile from within the extract and with both samples [redacted] being both processed alongside each other on initial quantification and amplification batches indicates that contamination has occurred at the point of the first Amplification set-up or earlier (e.g. quantification or extraction).

## Conclusion

During the course of investigation information has been gained that when viewed alongside other previous and subsequent quality events (namely OQI's #19330, 19349, 19477, & 19768) a picture of potential systematic quality failure of the quality processes from the automated extraction processes is present. Further information is required to further elucidate and rectify if necessary any problems. A full process audit (Audit #8227 – DNA IQ) has been commissioned to thoroughly review all facets of the automated extraction process. This had been planned as a post implementation review but has been brought forward in view of events mentioned above. An extra-ordinary meeting of the DNA Analysis management meeting was held 14/07/2008 and the following actions were agreed upon:

- Processing of Reference samples only on Extraction platform A (initial investigations indicated events were likely related to platform A)
- Processing of Casework samples on Extraction platform B in a checkerboard pattern with extraction reagent blanks (layout shown in Figure 6 below).
- Urgent progression of audit mentioned above and investigation into findings
- A full information review of results from automated extractions with documented quality events and extractions without documented quality events to gain further information

	1	2	3	4	5	6	7	8	9	10	11	12
A	Neg	sample	blank	sample	blank	sample	blank	sample	blank	sample	blank	sample
B	Pos	blank	sample	blank	sample	blank	sample	blank	sample	blank	sample	blank
C	blank	sample	blank	sample	blank	sample	blank	sample	blank	sample	blank	sample
D	sample	blank	sample	blank	sample	blank	sample	blank	sample	blank	sample	blank
E	blank	sample	blank	sample	blank	sample	blank	sample	blank	sample	blank	sample
F	sample	blank	sample	blank	sample	blank	sample	blank	sample	blank	sample	blank
G	blank	sample	blank	sample	blank	sample	blank	sample	blank	sample	blank	sample
H	sample	blank	sample	blank	sample	blank	sample	blank	sample	blank	sample	blank

Figure 6. Checkerboard arrangement of samples and extraction blanks on extraction batches during investigation period

# CaSS | Forensic and Scientific Services

A CLINICAL AND STATEWIDE SERVICE

Findings from the above mentioned audit and investigations will be documented in the quality system against the audit and in a separate investigation report once complete. This adverse event has been documented as OQ#19767 in the quality system.

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

